Nima Farzan - 04 Jun 2026 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Reporting relationship: Director
Issuer ticker: KROS
Reported as of: 04 Jun 2026
Net transaction value: -$28,166
SEC form: 4
Accepted by SEC: 08 Jun 2026, 16:37:53 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Keith Regnante, Attorney-in-Fact

Key filing fact

Nima Farzan filed Form 4 for Keros Therapeutics, Inc. (KROS) on 08 Jun 2026.

Key facts

This page summarizes Nima Farzan's Form 4 filing for Keros Therapeutics, Inc. (KROS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Jun 2026, 16:37.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: -$28,166.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001808296 Primary reporting owner

Farzan Nima

Relationship: Director
Address: C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON
Signature: /s/ Keith Regnante, Attorney-in-Fact
Signature date: 08 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KROS transaction

Common Stock

Sale

Transaction value: $28,166
Shares: -2,625
Change %: -21%
Price: $10.73
Shares after: 9,767
Date: 04 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.